Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian (Europe)
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian (Europe)
Man dies after helicopter crashes into field in South Yorkshire
30/10/2025
Almost all children in 73 areas of England live in low-income households
30/10/2025
A bellowing stag and the northern lights : photos of the day – Thursday
30/10/2025
Lib Dem members criticise ‘trans-exclusionary’ rule change for party elections
30/10/2025
South Yorkshire police officer jailed for blackmailing suspect
30/10/2025
Nabil Shaban obituary
30/10/2025